No Data
jiangsu bioperfectus technologies co.,ltd. (688399): the leader in molecular diagnostics, disturbance clearing, setting sail for a new cycle.
As a leading company in the field of molecular diagnostics, the company has a solid reserve in technology platform and product pipeline, especially demonstrating outstanding response speed in dealing with public health emergencies. Since 2024, the company's high base and impairment disturbances from before have been dealt with.
Jiangsu Shuoshi Biotechnology Co., Ltd. Report for the Third Quarter of 2024
Express News | jiangsu bioperfectus technologies co.,ltd.: obtained the registration certificate for dengue virus nucleic acid test kit medical instruments.
Express News | Jiangsu Bioperfectus Technologies Co., Ltd.: Net income in the first three quarters increased by 115.40% year-on-year.
Express News | Orient: Initiated coverage on jiangsu bioperfectus technologies co.,ltd. with a shareholding rating.
Jiangsu Bioperfectus Technologies Co.,Ltd. (688399): Focusing on "maternal and child health + infectious diseases", with outstanding research and development capabilities.
Deeply cultivating the in vitro diagnostics (IVD) sector, the operational capability continues to improve. Shuoshi was founded in 2010 and has been continuously consolidating its main advantages in molecular diagnostics over the years, while also making efforts in areas such as POCT, and actively exploring overseas markets, forming over 600.
No Data
No Data